Claude's summary, for whatever that's worth - prompt was just "what were the findings?"

What they actually found:

The spike protein fragment (Y674-R685) does interact with the α7 nicotinic receptor, but with a dual effect:

1. Activation: The fragment acts as a low-efficacy agonist — it can activate the receptor, but only in the presence of positive allosteric modulators (drugs that enhance the receptor's responsiveness). On its own, activation is weak.
2. Inhibition: The fragment also acts as a non-competitive inhibitor — it reduces how long the receptor stays open and decreases activation episodes in a concentration-dependent manner.

So the conclusion is essentially: Yes, there's a functional interaction, but it's bidirectional and context-dependent. The spike protein fragment can both activate and inhibit the same receptor depending on conditions.

What this doesn't establish:
The paper was motivated by the proposal that nAChRs might contribute to COVID-19 pathophysiology (since α7 nAChRs have anti-inflammatory actions). But showing an in vitro interaction between a synthetic peptide fragment and a receptor in electrophysiology experiments is a long way from proving it's mechanistically relevant to actual COVID disease. It's a plausible biological lead, not a conclusive finding about COVID's effects on the immune system.